Laneasha Eudell
Psychiatric/Mental Health · Syracuse, NYNPI 1811407745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 723 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,594 and has fallen 59.1% since, to $1,878 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 723 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Alkermes, Inc.$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Lundbeck LLC$956
- plus $5K from 17 others
What the payments were for
- Food & beverage$14,88998%
- Education$3332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 154 | $3,398 |
| Alkermes, Inc. | 62 | $1,606 |
| AbbVie | 92 | $1,422 |
| Teva Pharmaceuticals USA, Inc. | 58 | $1,286 |
| Johnson & Johnson | 34 | $1,174 |
| Lundbeck LLC | 58 | $956 |
| Sunovion Pharmaceuticals Inc. | 48 | $868 |
| Otsuka America Pharmaceutical, Inc. | 29 | $777 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $756 |
| Axsome Therapeutics, Inc. | 13 | $620 |
| Vanda Pharmaceuticals Inc. | 29 | $588 |
| Indivior Inc. | 24 | $413 |
| Neurocrine Biosciences, Inc. | 10 | $406 |
| Bausch Health US, LLC | 44 | $326 |
| Supernus Pharmaceuticals, Inc. | 7 | $158 |
| Gilead | 3 | $152 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Eisai Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Braeburn Inc. | 2 | $41 |
| Almatica Pharma LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,415
- CAPLYTA$1,414
- ARISTADA$1,404
- ARISTADA INITIO$351
- REXULTI$317
- INGREZZA$238
- VRAYLAR$231
- Austedo XR$217
- Auvelity$208
- SPRAVATO$165
- INVEGA SUSTENNA$146
- INVEGA TRINZA$146
- AUSTEDO$125
- COBENFY$125
- UZEDY$124
- QELBREE$122
- INVEGA$111
- Epclusa$110
How this compares
$15,222 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify AsimtufiiAripiprazole | 11 | $62,464 |
| RexultiBrexpiprazole | 25 | $35,616 |
| Abilify MaintenaAripiprazole | 14 | $34,611 |
| CaplytaLumateperone Tosylate | 19 | $31,524 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $11,522 |
| TrintellixVortioxetine Hydrobromide | 16 | $8,209 |
| Lurasidone Hcl | 19 | $7,403 |
| Lisdexamfetamine Dimesylate | 22 | $5,407 |
| Quetiapine Fumarate | 36 | $1,112 |
| Buspirone Hcl | 40 | $528 |
| Hydroxyzine Hcl | 20 | $426 |
| Bupropion XlBupropion Hcl | 14 | $356 |
| Cyproheptadine Hcl | 13 | $319 |
| Lithium Carbonate ErLithium Carbonate | 14 | $228 |
| Duloxetine Hcl | 20 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti, Abilify Maintena | $777 | $132,69050 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,398 | $31,52419 claims |
| Axsome Therapeutics, Inc.Auvelity | $620 | $11,52215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $756 | $8,20916 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $18721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Syracuse
- Sherie RamsgardSyracuse$52K
- Kyle GroshansSyracuse$10K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.